Docket Number:28A-1010328
Inventor:Jean Lu, Yu-Chuan Liu
IP Status:TW I623550
Abstract:
Bone loss diseases and bone fracture cause a lot of life lost and medical expense. Osteoporosis, one of the bone loss diseases, is a worldwide epidemic disease resulting from reduction of bone mass, which frequently leads to bone fracture. Most anti-osteoporosis drugs increase bone mass or regulate bone turnover rate. However, all the drugs for anti-osteoporosis drugs has side effect. Based on our un-biased ORF library screen, ApoA-1 was found to be the potential target for promoting the bone formation. ApoA-1 mimetic which has the same efficacy as ApoA-1 and can be taken by oral administration. Take advantage of this finding, ApoA-1 and its mimetic could be a drug for bone loss diseases (such as osteoporosis) and bone fracture.
Fields of Application:
- Bone loss diseases Such as Osteoporosis occurring in older people, post-menopausal women, or patients who have received long-term hormonal treatment or suffered from hyperthyroidism or tumors of adrenal glands.
- Bone fracture
Advantages when compared to the existing technologies:
- ApoA-1 mimetic can be given by oral administration in vivo, and the efficacy has been proven in animal experiment.
- Hyperlipidemia impaired anabolic effects of Parathyroid hormone (PTH), and ApoA-1 had the dramatic effect in the treatment for cardiovascular or obesity disease. According to this, PTH therapy may be replaced by ApoA-1.
- Osteosarcoma may occur by long-term PTH treatment. Based on the ability of ApoA-1 to reduce ovarian caner, the cure of ApoA-1 for osteoporosis may be the safety choice than PTH.
- Apo-1 mimetic has multiple functions, prevents the bone loss, increases the bone recovery rate, prevents cardiovascular diseases, blocks the formation of adipocytes, and maybe prevent cancer.
- For osteoporosis therapy, bisphosphonate is widely used in clinical. However several reports shown that bisphosphonate increase the incidence of osteonecrosis of the jaw. ApoA-1 should be substitute for bisphosphonate therapy.
- ApoA-1 increase the bone formation forty fold compare to induction medium. The efficacy to induce bone formation is excellent.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
